Autotaxin inhibitors: a patent review (2012-2016)

References

• Stefan C, Jansen S, Bollen M. NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci. 2005;30:542–550.
   PubMed Web of Science ®Google Scholar
• Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as sutotaxin, a multifunctional phosphodiesterase. J Biol Chem. 2002;277:39436–39442.
   PubMed Web of Science ®Google Scholar
• Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002;158:227–233.
   PubMed Web of Science ®Google Scholar
• Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3:582–591.
   PubMed Web of Science ®Google Scholar
• Okudaira S, Yukiura H, Aoki J. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie. 2010;92:698–706.
   PubMed Web of Science ®Google Scholar
• Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res. 2014;55:1192–1214.
   PubMed Web of Science ®Google Scholar
• Stoddard NC, Chun J. Promising pharmacological directions in the world of lysophosphatidic acid signaling. Biomol Ther (Seoul). 2015;23:1–11.
   PubMed Web of Science ®Google Scholar
• Sevastou I, Kaffe E, Mouratis MA, et al. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA2/LPC and ATX/LPA axes. Biochim Biophys Acta. 2013;1831:42–60.
   PubMed Web of Science ®Google Scholar
• Benesch MGK, Ko YM, McMullen TPW, et al. Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions. FEBS Lett. 2014;588:2712–2727.
   PubMed Web of Science ®Google Scholar
• Perrakis A, Moolenaar WH. Autotaxin: structure-function and signaling. J Lipid Res. 2014;55:1010–1018.
   PubMed Web of Science ®Google Scholar
• Barbayianni E, Kaffe E, Aidinis V, et al. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer. Prog Lipid Res. 2015;58:76–96.
   PubMed Web of Science ®Google Scholar
• Benesch MG, Tang X, Venkatraman G, et al. Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo. J Biomed Res. 2016;30:272–284.
   PubMed Web of Science ®Google Scholar
• Federico L, Jeong KJ, Vellano CP, et al. Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. J Lipid Res. 2016;57:25–35.
   PubMed Web of Science ®Google Scholar
• Parrill AL, Baker DL. Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts. Expert Opin Ther Pat. 2010;20:1619–1625.
   PubMed Web of Science ®Google Scholar
• Albers HMHG, Ovaa H. Chemical evolution of autotaxin inhibitors. Chem Rev. 2012;112:2593–2603.
   PubMed Web of Science ®Google Scholar
• Barbayianni E, Magrioti V, Moutevelis-Minakakis P, et al. Autotaxin inhibitors: a patent review. Expert Opin Ther Pat. 2013;23:1123–1132.
   PubMed Web of Science ®Google Scholar
• Castagna D, Budd DC, Macdonald SJF, et al. Development of autotaxin inhibitors: an overview of the patent and primary literature. J Med Chem. 2016;59:5604–5621.
   PubMed Web of Science ®Google Scholar
• Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 1992;267:2524–2529.
   PubMed Web of Science ®Google Scholar
• Hausmann J, Kamtekar S, Christodoulou E, et al. Structural basis for substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol. 2011;18:198–204.
   PubMed Web of Science ®Google Scholar
• Nishimasu H, Okudaira S, Hama K, et al. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol. 2011;18:205–212.
   PubMed Web of Science ®Google Scholar
• Jansen S, Callewaert N, Dewerte I, et al. An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D. J Biol Chem. 2007;282:11084–11091.
   PubMed Web of Science ®Google Scholar
• Jansen S, Andries M, Derua R, et al. Domain interplay mediated by an essential disulfide linkage is critical for the activity and secretion of the metastasis-promoting enzyme autotaxin. J Biol Chem. 2009;284:14296–14302.
   PubMed Web of Science ®Google Scholar
• Gijsbers R, Aoki J, Arai H, et al. The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett. 2003;538:60–64.
   PubMed Web of Science ®Google Scholar
• Fells JI, Lee SC, Fujiwara Y, et al. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface. Mol Pharmacol. 2013;84:415–424.
   PubMed Web of Science ®Google Scholar
• Hausmann J, Perrakis A, Moolenaar WH. Structure–function relationships of autotaxin, a secreted lysophospholipase D. Adv Biol regul. 2013;53:112–117.
   PubMedGoogle Scholar
• Yuelling LM, Fuss B. Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties. Biochim Biophys Acta. 2008;1781:525–530.
   PubMed Web of Science ®Google Scholar
• Giganti A, Rodriguez M, Fould B, et al. Murine and human autotaxin α, β, and γ isoforms: gene organization, tissue distribution, and biochemical characterization. J Biol Chem. 2008;283:7776–7789.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Okudaira S, Igarashi K, et al. Identification and biochemical characterization of a novel autotaxin isoform, ATXδ, with a four-amino acid deletion. J Biochem. 2012;151:89–97.
   PubMed Web of Science ®Google Scholar
• Clair T, Aoki J, Koh E, et al. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 2003;63:5446–5453.
   PubMed Web of Science ®Google Scholar
• Hait NC, Oskeritzian CA, Paugh SW, et al. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. BBA - Biomembranes. 2006;1758:2016–2026.
   PubMed Web of Science ®Google Scholar
• Tsuda S, Okudaira S, Moriya-Ito K, et al. Cyclic phosphatidic acid is produced by autotaxin in blood. J Biol Chem. 2006;281:26081–26088.
   PubMed Web of Science ®Google Scholar
• Aikawa S, Hashimoto T, Kano K, et al. Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem. 2015;157:81–89.
   PubMed Web of Science ®Google Scholar
• Tigyi G. Physiological responses to lysophosphatidic acid and related glycero-phospholipids. Prostaglandins Other Lipid Mediat. 2001;64:47–62.
   PubMed Web of Science ®Google Scholar
• Moolenaar WH, Van Meeteren LA, Giepmans BNG. The ins and outs of lysophosphatidic acid signaling. Bioessays. 2004;26:870–881.
   PubMed Web of Science ®Google Scholar
• Jesionowska A, Cecerska E, Dolegowska B. Methods for quantifying lysophosphatidic acid in body fluids: a review. Anal Biochem. 2014;453:38–43.
   PubMed Web of Science ®Google Scholar
• Contos JJ, Ishii I, Chun J. Lysophosphatidic acid receptors. Mol Pharmacol. 2000;58:1188–1196.
   PubMed Web of Science ®Google Scholar
• Contos JJ, Fukushima N, Weiner JA, et al. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA. 2000;97:13384–13389.
   PubMed Web of Science ®Google Scholar
• Archbold JK, Martin JL, Sweet MJ. Towards selective lysophospholipid GPCR modulators. Trends Pharmacol Sci. 2014;35:219–226.
   PubMed Web of Science ®Google Scholar
• Hope JM, Wang FQ, Whyte JS, et al. LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol. 2009;112:215–223.
   PubMed Web of Science ®Google Scholar
• Ohuchi H, Hamada A, Matsuda H, et al. Expression patterns of the lysophospholipid receptor genes during mouse early development. Dev Dyn. 2008;237:3280–3294.
   PubMed Web of Science ®Google Scholar
• Ye X, Hama K, Contos JJ, et al. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature. 2005;435:104–108.
   PubMed Web of Science ®Google Scholar
• Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem. 2003;278:25600–25606.
   PubMed Web of Science ®Google Scholar
• Choi JW, Herr DR, Noguchi K, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol. 2010;50:157–186.
   PubMed Web of Science ®Google Scholar
• Sumida H, Noguchi K, Kihara Y, et al. LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood. 2010;116:5060–5070.
   PubMed Web of Science ®Google Scholar
• Kotarsky K, Boketoft A, Bristulf J, et al. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther. 2006;318:619–628.
   PubMed Web of Science ®Google Scholar
• Lee CW, Rivera R, Gardell S, et al. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem. 2006;281:23589–23597.
   PubMed Web of Science ®Google Scholar
• Pasternack SM, Von Kugelgen I, Aboud KA, et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet. 2008;40:329–334.
   PubMed Web of Science ®Google Scholar
• Yanagida K, Masago K, Nakanishi H, et al. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/lpa6. J Biol Chem. 2009;284:17731–17741.
   PubMed Web of Science ®Google Scholar
• Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. BBA Mol Cell Biol Lipids. 2008;1781:513–518.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang W, Evans JF, et al. Autotaxin, pruritus and primary biliary cholangitis (PBC). Autoimmun Rev. 2016;15:795–800.
   PubMed Web of Science ®Google Scholar
• Van Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol. 2006;26:5015–5022.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Okudaira S, Kishi Y, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006;281:25822–25830.
   PubMed Web of Science ®Google Scholar
• Gierse J, Thorarensen A, Beltey K, et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther. 2010;334:310–317.
   PubMed Web of Science ®Google Scholar
• Albers HM, Dong A, Van Meeteren LA, et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci USA. 2010;107:7257–7262.
   PubMed Web of Science ®Google Scholar
• Ferry G, Moulharat N, Pradere JP, et al. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther. 2008;327:809–819.
   PubMed Web of Science ®Google Scholar
• Fotopoulou S, Oikonomou N, Grigorieva E, et al. ATX expression and LPA signalling are vital for the development of the nervous system. Dev Biol. 2010;339:451–464.
   PubMed Web of Science ®Google Scholar
• Ferry G, Tellier E, Try A, et al. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation: up-regulated expression with adipocyte differentiation and obesity. J Biol Chem. 2003;278:18162–18169.
   PubMed Web of Science ®Google Scholar
• Sato K, Malchinkhuu E, Muraki T, et al. Identification of autotaxin as a neurite retraction-inducing factor of PC12 cells in cerebrospinal fluid and its possible sources. J Neurochem. 2005;92:904–914.
   PubMed Web of Science ®Google Scholar
• Tokumura A, Kume T, Fukuzawa K, et al. Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life Sci. 2007;80:1641–1649.
   PubMed Web of Science ®Google Scholar
• Nochi H, Tomura H, Tobo M, et al. Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells. J Immunol. 2008;181:5111–5119.
   PubMed Web of Science ®Google Scholar
• Oikonomou N, Mouratis MA, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;47:566–574.
   PubMed Web of Science ®Google Scholar
• Nikitopoulou I, Oikonomou N, Karouzakis E, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med. 2012;209:925–933.
   PubMed Web of Science ®Google Scholar
• Kanda H, Newton R, Klein R, et al. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol. 2008;9:415–423.
   PubMed Web of Science ®Google Scholar
• Fuss B, Baba H, Phan T, et al. Phosphodiesterase I, a novel adhesion molecule and/or cytokine involved in oligodendrocyte function. J Neurosci. 1997;17:9095–9103.
   PubMed Web of Science ®Google Scholar
• Moolenaar WH. Lysophospholipids in the limelight: autotaxin takes center stage. J Cell Biol. 2002;158:197–199.
   PubMed Web of Science ®Google Scholar
• Jansen S, Stefan C, Creemers JW, et al. Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J Cell Sci. 2005;118:3081–3089.
   PubMed Web of Science ®Google Scholar
• Koike S, Keino-Masu K, Ohto T, et al. The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide. Genes Cells. 2006;11:133–142.
   PubMed Web of Science ®Google Scholar
• Katsifa A, Kaffe E, Nikolaidou-Katsaridou N, et al. The bulk of autotaxin activity is dispensable for adult mouse life. Plos ONE. 2015;10:e0143083.
   PubMed Web of Science ®Google Scholar
• Lee SC, Fujiwara Y, Liu J, et al. Autotaxin, LPA receptors (1 and 5) exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis. Mol Cancer Res. 2015;13:174–185.
   PubMed Web of Science ®Google Scholar
• Lee SC, Fujiwara Y, Tigyi GJ. Uncovering unique roles of LPA receptors in the tumor microenvironment. Receptors Clin Investig. 2015;2:e440.
   PubMedGoogle Scholar
• Gotoh M, Fujiwara Y, Yue J, et al. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans. 2012;40:31–36.
   PubMed Web of Science ®Google Scholar
• Rancoule C, Dusaulcy R, Treguer K, et al. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. Biochimie. 2014;96:140–143.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Ikeda H, Nakamura K, et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol. 2007;41:616–623.
   PubMed Web of Science ®Google Scholar
• Knowlden S, Georas SN. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. J Immunol. 2014;192:851–857.
   PubMed Web of Science ®Google Scholar
• Orosa B, García S, Conde C. The autotaxin–lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis. Eur J Pharmacol. 2015;765:228–233.
   PubMed Web of Science ®Google Scholar
• Moolenaar WH, Perrakis A. Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol. 2011;12:674–679.
   PubMed Web of Science ®Google Scholar
• Teo K, Brunton VG. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer. Biochem J. 2014;463:157–165.
   PubMed Web of Science ®Google Scholar
• Benesch MG, Tang X, Maeda T, et al. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 2014;28:2655–2666.
   PubMed Web of Science ®Google Scholar
• Brindley DN, Lin FT, Tigyi GJ. Role of the autotaxin–lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim Biophys Acta. 2013;1831:74–85.
   PubMed Web of Science ®Google Scholar
• Merchant TE, Kasimos JN, De Graaf PW, et al. Phospholipid profiles of human colon cancer using 31P magnetic resonance spectroscopy. Int J Colorectal Dis. 1991;6:121–126.
   PubMed Web of Science ®Google Scholar
• Leblanc R, Peyruchaud O. New insights into the autotaxin/LPA axis in cancer development and metastasis. Exp Cell Res. 2015;333:183–189.
   PubMed Web of Science ®Google Scholar
• Zuckerman V, Sokolov E, Swet JH, et al. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells. Oncotarget. 2016;7:2951–2967.
   PubMed Web of Science ®Google Scholar
• Liu S, Murph M, Panupinthu N, et al. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle. 2009;8:3695–3701.
   PubMed Web of Science ®Google Scholar
• Samadi N, Bekele R, Capatos D, et al. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie. 2011;93:61–70.
   PubMed Web of Science ®Google Scholar
• Willier S, Butt E, Grunewald TG. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell. 2013;105:317–333.
   PubMed Web of Science ®Google Scholar
• Seo EJ, Kwon YW, Jang IH, et al. Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism. Stem Cells. 2016;34:551–564.
   PubMed Web of Science ®Google Scholar
• Gaetano CG, Samadi N, Tomsig JL, et al. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol Carcinog. 2009;48:801–809.
   PubMed Web of Science ®Google Scholar
• Ptaszynska MM, Pendrak ML, Stracke ML, et al. Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res. 2010;8:309–321.
   PubMed Web of Science ®Google Scholar
• Park SY, Jeong KJ, Panupinthu N, et al. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene. 2011;30:1351–1359.
   PubMed Web of Science ®Google Scholar
• Boucharaba A, Serre CM, Gres S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004;114:1714–1725.
   PubMed Web of Science ®Google Scholar
• David M, Wannecq E, Descotes F, et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLOS ONE. 2010;5:e9741.
   PubMed Web of Science ®Google Scholar
• Leblanc R, Lee SC, David M, et al. Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone. Blood. 2014;124:3141–3150.
   PubMed Web of Science ®Google Scholar
• Hoelzinger DB, Mariani L, Weis J, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia. 2005;7:7–16.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–1961.
   PubMed Web of Science ®Google Scholar
• Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14:45–54.
   PubMed Web of Science ®Google Scholar
• Georas SN, Berdyshev E, Hubbard W, et al. Lysophosphatidic acid is detectable in human bronchoalveolar lavage fluids at baseline and increased after segmental allergen challenge. Clin Exp Allergy. 2007;37:311–322.
   PubMed Web of Science ®Google Scholar
• Park GY, Lee YG, Berdyshev E, et al. Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am J Respir Crit Care Med. 2013;188:928–940.
   PubMed Web of Science ®Google Scholar
• Knowlden SA, Hillman SE, Chapman TJ, et al. Novel inhibitory effect of an LPA2 agonist on allergen-driven airway inflammation. Am J Respir Cell Mol Biol. 2016;54:402–409.
   PubMed Web of Science ®Google Scholar
• Orosa B, Garcia S, Martinez P, et al. Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis. Ann Rheum Dis. 2014;73:298–305.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Ikeda H, Nakamura K, et al. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci. 2007;81:1009–1015.
   PubMed Web of Science ®Google Scholar
• Balood M, Zahednasab H, Siroos B, et al. Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis. Hum Immunol. 2014;75:411–413.
   PubMed Web of Science ®Google Scholar
• Zahednasab H, Balood M, Harirchian MH, et al. Increased autotaxin activity in multiple sclerosis. J Neuroimmunol. 2014;273:120–123.
   PubMed Web of Science ®Google Scholar
• Van Meeteren LA, Ruurs P, Christodoulou E, et al. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem. 2005;280:21155–21161.
   PubMed Web of Science ®Google Scholar
• Tokumura A, Miyake M, Yoshimoto O, et al. Metal-lon stimulation and inhibition of lysophospholipase D which generates bioactive lysophosphatidic acid in rat plasma. Lipids. 1998;33:1009–1015.
   PubMed Web of Science ®Google Scholar
• Murph M, Tanaka T, Pang J, et al. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Meth Enzymol. 2007;433:1–25.
   PubMed Web of Science ®Google Scholar
• Scherer M, Schmitz G, Liebisch G. High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic acid in plasma samples by liquid chromatography-tandem mass spectrometry. Clin Chem. 2009;55:1218–1222.
   PubMed Web of Science ®Google Scholar
• Imamura S, Horiuti Y. Enzymatic determination of phospholipase D activity with choline oxidase. J Biochem. 1978;83:677–680.
   PubMed Web of Science ®Google Scholar
• Albers HMHG, Van Meeteren LA, Egan DA, et al. Discovery and optimization of boronic acid based inhibitors of autotaxin. J Med Chem. 2010;53:4958–4967.
   PubMed Web of Science ®Google Scholar
• Takakusa H, Kikuchi K, Urano Y, et al. Design and synthesis of an enzyme-cleavable sensor molecule for phosphodiesterase activity based on fluorescence resonance energy transfer. J Am Chem Soc. 2002;124:1653–1657.
   PubMed Web of Science ®Google Scholar
• Ferguson CG, Bigman CS, Richardson RD, et al. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org Lett. 2006;8:2023–2026.
   PubMed Web of Science ®Google Scholar
• Vaiana AC, Neuweiler H, Schulz A, et al. Fluorescence quenching of dyes by tryptophan: interactions at atomic detail from combination of experiment and computer simulation. J Am Chem Soc. 2003;125:14564–14572.
   PubMed Web of Science ®Google Scholar
• Cavalli S, Houben AJS, Albers HMHG, et al. Development of an activity-based probe for autotaxin. ChemBioChem. 2010;11:2311–2317.
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Okabe T, Okudaira S, et al. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe. ACS Chem Biol. 2013;8:1713–1721.
   PubMed Web of Science ®Google Scholar
• Hoeglund AB, Howard AL, Wanjala IW, et al. Characterization of non-lipid autotaxin inhibitors. Bioorg Med Chem. 2010;18:769–776.
   PubMed Web of Science ®Google Scholar
• Pfizer. Pyrimidine and pyridine derivatives useful in therapy. WO2013054185A1. 2013.
   Google Scholar
• Eli LC. Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain. WO2014110000A1. 2014.
   Google Scholar
• Eli LC. Imidazo pyridine compounds. WO2014143583A1. 2014.
   Google Scholar
• Eli LC. Dihydropyrido pyrimidine compounds as autotaxin inhibitors. WO2014168824A1. 2014.
   Google Scholar
• Jones SB, Pfeifer LA, Bleisch TJ, et al. Novel autotaxin inhibitors for the treatment of osteoarthritis pain: lead optimization via structure-based drug design. ACS Med Chem Lett. 2016;7:857–861.
   PubMed Web of Science ®Google Scholar
• Thirunavukkarasu K, Tan B, Swearingen CA, et al. Pharmacological characterization of a potent inhibitor of autotaxin in animal models of inflammatory bowel disease and multiple sclerosis. J Pharmacol Exp Ther. 2016;359:207–214.
   PubMed Web of Science ®Google Scholar
• Mitsubishi Tanabe Pharma Corporation. Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof. WO2015163435A1. 2015.
   Google Scholar
• The University of Tokyo; Tohoku University; Shionogi & Co. 8-Substituted imidazopyrimidinone derivative having autotaxin inhibitory activity. WO2014133112 A1. 2014.
   Google Scholar
• The University of Tokyo; Tohoku University; Shionogi & Co. 1-Substituted imidazopyrimidinone derivative having autotaxin-inhibiting activity. WO2015064714A1. 2015.
   Google Scholar
• The University of Tokyo; Tohoku University; Shionogi & Co. Pyrimidinone derivative having autotaxin-inhibitory activity. WO2016031987A1. 2016.
   Google Scholar
• Hoffmann-La Roche. New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors. WO2014139978A1. 2014.
   Google Scholar
• Hoffmann-La Roche. New bicyclic derivatives. WO2014048865A1. 2014.
   Google Scholar
• Hoffmann-La Roche. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors. WO2015144605A1. 2015.
   Google Scholar
• Biogen MA Inc. ATX modulating agents. WO2015188051A1. 2015.
   Google Scholar
• The University of Tokyo; Tohoku University; Shionogi & Co. Fused pyrazole derivative having autotaxin inhibitory activity. WO2015129821A1. 2015.
   Google Scholar
• Biogen Idec Inc. ATX modulating agents. WO2014018881A1. 2014.
   Google Scholar
• Biogen Idec Inc. ATX modulating agents. WO2014018887A1. 2014.
   Google Scholar
• Biogen Idec Inc. Compounds that are S1P modulating agents and/or ATX modulating agents. WO2014018891A1. 2014.
   Google Scholar
• Biogen Idec Inc. Compounds that are S1P modulating agents and/or ATX modulating agents. WO2014025708A1. 2014.
   Google Scholar
• Biogen Idec Inc. Compounds that are S1P modulating agents and/or ATX modulating agents. WO2014025709A1. 2014.
   Google Scholar
• Pharmakea Inc. Heterocyclic vinyl autotaxin inhibitor compounds. WO2015042052A1. 2015.
   Google Scholar
• Pharmakea Inc. Vinyl autotaxin inhibitor compounds. WO2015042053A1. 2015.
   Google Scholar
• Pharmakea Inc. Autotaxin inhibitor compounds. WO2015048301A1. 2015.
   Google Scholar
• Pharmakea Inc. Tetracyclic autotaxin inhibitors. WO2015077502A1. 2015.
   Google Scholar
• Pharmakea Inc. Autotaxin inhibitor compounds. WO2015077503A1. 2015.
   Google Scholar
• Pharmakea Inc. Methods and compositions for the treatment of metabolic disorders. WO2016028686A1. 2016.
   Google Scholar
• Stein AJ, Bain G, Prodanovich P, et al. Structural basis for inhibition of human autotaxin by four potent compounds with distinct modes of binding. Mol Pharmacol. 2015;88:982–992.
   PubMed Web of Science ®Google Scholar
• Merck Patent GMBH. Piperidine and piperazine derivatives. WO2009046841A2. 2009.
   Google Scholar
• Merck Patent GMBH. Heterocyclic compounds as autotaxin inhibitors. WO2010112116A1. 2010.
   Google Scholar
• Merck Patent GMBH. Piperidine and piperazine derivatives as autotaxin inhibitors. WO2010115491A2. 2010.
   Google Scholar
• Novartis. Autotaxin inhibitors. WO2014097151A2. 2014.
   Google Scholar
• Novartis. Autotaxin inhibitors. US2014171403A1. 2014.
   Google Scholar
• Novartis. Autotaxin inhibitors. WO2015162558A1. 2015.
   Google Scholar
• Novartis. Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core. WO2015008230A1. 2015.
   Google Scholar
• Novartis. Autotaxin inhibitors. WO2015008229A1. 2015.
   Google Scholar
• Biogen Idec Inc. S1P and/or ATX modulating agents. WO2014152725A1. 2014.
   Google Scholar
• Hoffmann-La Roche. Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors. WO2015144609A1. 2015.
   Google Scholar
• X-Rx Discovery Inc. Substituted spirocydic inhibitors of autotaxin. WO2015154023A1. 2015.
   Google Scholar
• X-Rx Discovery Inc. Substituted N-(2-(amino)-2-oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of LPA-dependent or LPA-mediated diseases. WO2015175171A1. 2015.
   Google Scholar
• Biogen Idec Inc. S1P and/or ATX modulating agents. WO2014081752A1. 2014.
   Google Scholar
• Biogen Idec Inc. S1P and/or ATX modulating agents. WO2014081756A1. 2014.
   Google Scholar
• ONO Pharmaceutical Co. Tetrahydrocarboline derivative. WO2012005227A1. 2012.
   Google Scholar
• ONO Pharmaceutical Co. Tetrahydrocarboline derivative. WO2012127885A1. 2012.
   Google Scholar
• Saga H, Ohhata A, Hayashi A, et al. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension. PLOS ONE. 2014;9:e93230.
   Google Scholar
• Venkatraman G, Benesch MG, Tang X, et al. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment. FASEB J. 2015;29:772–785.
   PubMed Web of Science ®Google Scholar
• Benesch MG, Ko YM, Tang X, et al. Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer. Endocr Relat Cancer. 2015;22:593–607.
   PubMed Web of Science ®Google Scholar
• Galapagos NV. Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders. WO2014139882A1. 2014.
   Google Scholar
• Galapagos NV Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders. WO2014202458A1. 2014.
   Google Scholar
• Galapagos NV. Belgium. [ cited 2016 Sep 5]. Available from: http://www.glpg.com/docs/view/573b49bf4c48b-en
   Google Scholar
• Galapagos NV. Belgium. [ cited 2016 Sep 5]. Available from: http://files.glpg.com/docs/website_1/Poster_ERS_2015_final.pdf
   Google Scholar
• Ribomic Inc. Aptamer inhibiting biological activity of autotaxin by binding with autotaxin, and use thereof. WO2015147290A1. 2015.
   Google Scholar
• Ribomic Inc. Aptamer for bonding to autotaxin and inhibiting biological activity of autotaxin, and use for same. WO2015163458A1. 2015.
   Google Scholar
• Kato K, Ikeda H, Miyakawa S, et al. Structural basis for specific inhibition of autotaxin by a DNA aptamer. Nat Struct Mol Biol. 2016;23:395–401.
   PubMed Web of Science ®Google Scholar
• Janssen Biotech Inc. Human autotaxin antibodies and methods of use. WO2013138241A1. 2013.
   Google Scholar
• Vrontaki E, Melagraki G, Kaffe E, et al. Computer aided drug design approaches for identification of novel autotaxin (ATX) inhibitors. Curr Med Chem. 2016;23:1708–1724.
   PubMed Web of Science ®Google Scholar
• Katsamakas S, Bermperoglou E, Hadjipavlou-Litina D. Considering autotaxin inhibitors in terms of 2D-QSAR and 3D-mapping-review and evaluation. Curr Med Chem. 2015;22:1428–1461.
   PubMed Web of Science ®Google Scholar
• Fells JI, Lee SC, Norman DD, et al. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif. FEBS J. 2014;281:1017–1028.
   PubMed Web of Science ®Google Scholar
• Kihara Y, Mizuno H, Chun J. Lysophospholipid receptors in drug discovery. Exp Cell Res. 2015;333:171–177.
   PubMed Web of Science ®Google Scholar
• Keune WJ, Hausmann J, Bolier R, et al. Steroid binding to autotaxin links bile salts and lysophosphatidic acid signaling. Nat Commun. 2016;7:11248.
   PubMed Web of Science ®Google Scholar